

Resource Summary Report

Generated by [dkNET](#) on Sep 16, 2026

AGS

RRID:CVCL_0139

Type: Cell Line

Proper Citation

RRID:CVCL_0139

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0139

Proper Citation: RRID:CVCL_0139

Description: Cell line AGS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Gastric adenocarcinoma

Defining Citation: [PMID:1370612](#), [PMID:6678861](#), [PMID:6831414](#), [PMID:10402490](#), [PMID:15767549](#), [PMID:17509637](#), [PMID:18804159](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25485619](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27445371](#), [PMID:28196595](#), [PMID:29435981](#), [PMID:29717028](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34466148](#), [PMID:35122114](#), [PMID:35839778](#)

Comments: Virology: Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS (PubMed=17509637; PubMed=27445371)., Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: JFCR45 cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AGS

Cross References: BTO:BTO_0001007, CLO:CLO_0001686, EFO:EFO_0002109, MCCL:MCC:0000032, CLDB:cl258, CLDB:cl5134, AddexBio:C0023004/4958,

ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1739, BCRC:60102, BCRJ:0311, BioGRID_ORCS_Cell_line:332, BioSample:SAMN03471028, BioSample:SAMN03471416, BioSample:SAMN10988305, cancercellines:CVCL_0139, CCRID:1101HUM-PUMC000480, CCRID:3101HUMTCHu232, CCRID:4201HUM-CCTCC00247, CCTCC:GDC0247, Cell_Model_Passport:SIDM00850, ChEMBL-Cells:ChEMBL3308078, ChEMBL-Targets:ChEMBL613860, CLS:300408, Cosmic:685586, Cosmic:848149, Cosmic:868235, Cosmic:873708, Cosmic:887255, Cosmic:888819, Cosmic:906790, Cosmic:1067211, Cosmic:1090463, Cosmic:1187266, Cosmic:1294957, Cosmic:1482073, Cosmic:1518239, Cosmic:1582429, Cosmic:1627261, Cosmic:1995340, Cosmic:2036659, Cosmic:2069770, Cosmic:2484954, Cosmic:2823227, Cosmic-CLP:906790, DepMap:ACH-000880, ECACC:89090402, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:906790, GEO:GSM267417, GEO:GSM267424, GEO:GSM267431, GEO:GSM267438, GEO:GSM552354, GEO:GSM562392, GEO:GSM618009, GEO:GSM618010, GEO:GSM618011, GEO:GSM618012, GEO:GSM827400, GEO:GSM828792, GEO:GSM843440, GEO:GSM886864, GEO:GSM887929, GEO:GSM1237672, GEO:GSM1237697, GEO:GSM1250894, GEO:GSM1250895, GEO:GSM1250896, GEO:GSM1250897, GEO:GSM1374389, GEO:GSM1374390, GEO:GSM1669595, GEO:GSM2983073, GEO:GSM2983074, GEO:GSM2983075, GEO:GSM2983076, IARC_TP53:21171, IBRC:C10071, IGRhCellID:AGS, IZSLER:BS TCL 135, KCB:KCB 200708YJ, KCLB:21739, LiGeA:CCLE_280, LINCS_HMS:50004, LINCS_LDP:LCL-1893, Lonza:727, NCBI_Iran:C131, PharmacDB:AGS_56_2019, PRIDE:PXD000722, PRIDE:PXD030304, Progenetix:CVCL_0139, PubChem_Cell_line:CVCL_0139, TOKU-E:522, Ubigen:YC-C003, Wikidata:Q54748713

ID: CVCL_0139

Record Creation Time: 20220427T215214+0000

Record Last Update: 20260913T012118+0000

Ratings and Alerts

No rating or validation information has been found for AGS.

No alerts have been found for AGS.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 143 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Zhao J, et al. (2026) Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism. *Cell reports*, 45(2), 116863.

Zhang J, et al. (2026) Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer. *International immunopharmacology*, 175, 116453.

B?dzi?ska A, et al. (2026) The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. *Cell communication and signaling : CCS*, 24(1).

Laurenziello P, et al. (2026) Salinomycin as a death switch: how gastric cancer cells choose their demise. *Cell death discovery*, 12(1).

Liu W, et al. (2026) SEVs-carried ENPP1 regulates DCs' activation and inhibits the formation of tertiary lymphoid structures in gastric cancer. *Journal of gastroenterology*.

Wei Y, et al. (2026) High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. *Acta pharmaceutica Sinica. B*, 16(7), 4524.

Xu D, et al. (2026) LINC01106 drives gastric cancer progression and tumor immune microenvironment remodeling via the miR-361-3p/DTL axis. *Cellular signalling*, 141, 112395.

Liao F, et al. (2026) *Streptococcus anginosus*-generated succinate promotes the progression of gastric cancer via the succinate/SUCNR1/ABRAXAS1 axis. *Cell reports*, 45(3), 117047.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. *bioRxiv : the preprint server for biology*.

Shen X, et al. (2026) A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer. *Oncogene*, 45(31), 3181.

Kunnathattil M, et al. (2026) Chemical Profiling and ROS-Dependent Antiproliferative Activity of *Artemisia nilagirica* (C.B.Clarke) Pamp. (Asteraceae) Essential Oil in Human Gastric Adenocarcinoma Cells. *Chemistry & biodiversity*, 23(7), e71487.

Li Y, et al. (2026) The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8. *The FEBS journal*.

Li L, et al. (2026) The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer. *Frontiers in oncology*, 16, 1728472.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Liu W, et al. (2026) DEK recruits KAT6A regulate H3K27ac/c-myc axis to drive enhanced glycolysis and immune escape in gastric cancer. *Free radical biology & medicine*, 255, 35.

Lu Y, et al. (2026) GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. *Cancer research*, 86(10),

2429.

He J, et al. (2026) UBE2B Drives NF- κ B Signaling and Gastric Cancer Progression through BIRC2-Mediated K63-Linked Ubiquitination of TRAF1. *Molecular cancer research* : MCR, 24(6), 487.

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. *Cell reports. Medicine*, 7(2), 102618.

Yan Y, et al. (2026) Orientin inhibits cyclin E/cyclin A-CDK2 to induce growth arrest at senescence in human gastric cancer cells. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*, 215, 116227.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.